Explore
Validate
LearnMA5-17106
antibody from Invitrogen Antibodies
Targeting: KEAP1
INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [3]
- Immunocytochemistry [1]
- Flow cytometry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-17106 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- KEAP1 Monoclonal Antibody (1F10B6)
- Antibody type
- Monoclonal
- Antigen
- Purifed from natural sources
- Description
- MA5-17106 targets KEAP1 in FACS, ICC, IF and WB applications and shows reactivity with Human and Mouse samples.
- Antibody clone number
- 1F10B6
- Concentration
- Conc. Not Determined
Submitted references Activated PKB/GSK-3β synergizes with PKC-δ signaling in attenuating myocardial ischemia/reperfusion injury via potentiation of NRF2 activity: Therapeutic efficacy of dihydrotanshinone-I.
BML-111 treatment prevents cardiac apoptosis and oxidative stress in a mouse model of autoimmune myocarditis.
Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer.
Zeng H, Wang L, Zhang J, Pan T, Yu Y, Lu J, Zhou P, Yang H, Li P
Acta pharmaceutica Sinica. B 2021 Jan;11(1):71-88
Acta pharmaceutica Sinica. B 2021 Jan;11(1):71-88
BML-111 treatment prevents cardiac apoptosis and oxidative stress in a mouse model of autoimmune myocarditis.
Jaén RI, Fernández-Velasco M, Terrón V, Sánchez-García S, Zaragoza C, Canales-Bueno N, Val-Blasco A, Vallejo-Cremades MT, Boscá L, Prieto P
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2020 Aug;34(8):10531-10546
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2020 Aug;34(8):10531-10546
Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer.
Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, Huang TH, Huang CF, Lai JM
Cancers 2019 Jul 17;11(7)
Cancers 2019 Jul 17;11(7)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of KEAP1 using a KEAP1 monoclonal antibody (Product # MA5-17106) against a human KEAP1 recombinant protein.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of KEAP1 using a KEAP1 monoclonal antibody (Product # MA5-17106) against a human KEAP1 recombinant protein.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of KEAP1 using KEAP1 monoclonal antibody (Product # MA5-17106) in NIH3T3 (1), and A549 (2) cell lysate.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of HeLa cells using KEAP1 monoclonal antibody (Product # MA5-17106) (Green). Blue: DRAQ5 fluorescent DNA dye. Red: actin filaments have been labeled with phalloidin.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometric analysis of HepG2 cells using KEAP1 monoclonal antibody (Product # MA5-17106) (green) and negative control (purple).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometric analysis of HepG2 cells using KEAP1 monoclonal antibody (Product # MA5-17106) (green) and negative control (purple).
